IL323014A - תכשירים ושיטות שימוש בהם - Google Patents
תכשירים ושיטות שימוש בהםInfo
- Publication number
- IL323014A IL323014A IL323014A IL32301425A IL323014A IL 323014 A IL323014 A IL 323014A IL 323014 A IL323014 A IL 323014A IL 32301425 A IL32301425 A IL 32301425A IL 323014 A IL323014 A IL 323014A
- Authority
- IL
- Israel
- Prior art keywords
- oxalate
- fab
- disease
- docket
- february
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363448753P | 2023-02-28 | 2023-02-28 | |
| US202363604415P | 2023-11-30 | 2023-11-30 | |
| PCT/US2024/017626 WO2024182489A1 (en) | 2023-02-28 | 2024-02-28 | Compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL323014A true IL323014A (he) | 2025-10-01 |
Family
ID=92590151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL323014A IL323014A (he) | 2023-02-28 | 2024-02-28 | תכשירים ושיטות שימוש בהם |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4673126A1 (he) |
| IL (1) | IL323014A (he) |
| WO (1) | WO2024182489A1 (he) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2639863B1 (es) * | 2017-03-10 | 2018-09-20 | Universidad De Granada | Compuestos para el tratamiento de enfermedades causadas por la acumulación de oxalato |
-
2024
- 2024-02-28 WO PCT/US2024/017626 patent/WO2024182489A1/en not_active Ceased
- 2024-02-28 EP EP24764515.3A patent/EP4673126A1/en active Pending
- 2024-02-28 IL IL323014A patent/IL323014A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4673126A1 (en) | 2026-01-07 |
| WO2024182489A1 (en) | 2024-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Ferroptosis and endoplasmic reticulum stress in ischemic stroke | |
| Romero et al. | The race to bash NASH: emerging targets and drug development in a complex liver disease | |
| CN101252924B (zh) | 通过血清视黄醇、血清视黄醇结合蛋白(rbp)和/或血清视黄醇-rbp调节治疗眼部疾病的方法和组合物 | |
| Feng et al. | Lipid metabolism of hepatocellular carcinoma impacts targeted therapy and immunotherapy | |
| Tian et al. | Resveratrol ameliorates myocardial ischemia/reperfusion induced necroptosis through inhibition of the Hippo pathway | |
| Li et al. | Genetic and pharmacological inhibition of fatty acid-binding protein 4 alleviated inflammation and early fibrosis after toxin induced kidney injury | |
| Bradbury | CFTR and cystic fibrosis: a need for personalized medicine | |
| Seidel et al. | Annexin A1 modulates macula densa function by inhibiting cyclooxygenase 2 | |
| Lee et al. | BRD2‐specific inhibitor, BBC0403, inhibits the progression of osteoarthritis pathogenesis in osteoarthritis‐induced C57BL/6 male mice | |
| Yang et al. | Intestinal GSTpi deficiency exacerbates the severity of experimental hyperlipidemic acute pancreatitis | |
| Sun et al. | Brown adipose Vanin-1 is required for the maintenance of mitochondrial homeostasis and prevents diet-induced metabolic dysfunction | |
| Zhang et al. | Transcription factor EB modulates the homeostasis of reactive oxygen species in intestinal epithelial cells to alleviate inflammatory bowel disease | |
| IL323014A (he) | תכשירים ושיטות שימוש בהם | |
| WO2022226191A9 (en) | Methods of stabilizing the neuronal proteome against collapse and protecting vascular cells | |
| US20210222172A1 (en) | Methods of Treating Porphyria | |
| JP2023538612A (ja) | 糖尿病治療及びベータ細胞再生のための方法及び組成物 | |
| CN115955970A (zh) | 使用Pelorol衍生物治疗SHIP1介导的疾病的方法 | |
| Xia et al. | The EZH2 selective inhibitor ZLD1039 attenuates UUO-induced renal fibrosis by suppressing YAP activation | |
| Sun et al. | OTUD7B inhibited hepatic injury from NAFLD by inhibiting K48-linked ubiquitination and degradation of β-catenin | |
| EP3517108A1 (en) | Application of src homology region 2-containing protein tyrosine phosphatase-1 agonist for improving fibrosis | |
| Sheng et al. | Cyclophilin J limits linear ubiquitin signaling and controls colorectal cancer progression | |
| US20220079966A1 (en) | Hyaluronan synthesis inhibition for treating autoimmune, inflammatory, fibrotic, or proliferative diseases or disorders | |
| JP2008505145A (ja) | 排出ポンプ阻害剤を用いてペプチドデホルミラーゼ阻害剤の感受性を増加するための方法 | |
| Shen et al. | Methyl gallate and hyaluronic acid-nanoconjugate targeting HSP90β for osteoarthritis therapy | |
| Bairos | Cholesterol ester metabolism governs intracellular cholesterol crystal formation |